It’s personal

Improving the lives of patients is a personal matter for each and every member of our team at Protagen. You’ll see this in the passion we apply to the discovery, identification, and validation of novel biomarker panels for better diagnostic (Dx) and companion diagnostic (CDx) tests. It is demonstrated by the commitment and expertise we bring to our partnerships when working on clinical development programs. Our dedication to advancing diagnostics for personalized medicine is evident in everything we do.

Diagnostics Differentiated

We are adding a new dimension to the world of diagnostics. Our SeroTag biomarker development engine delivers unique biomarker signatures. The disease-specific signatures that we identify, often based on novel markers, are the basis for new diagnostic strategies that will improve the differentiation and stratification of patients. The result is a new medical scenario in which disease states are recognized earlier, and medical care can be more specifically and effectively provided.

Learn more

News

Protagen announces CE Mark for its proprietary Multilisa® BICD2 test for better diagnosis of Systemic Sclerosis

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced that it gained CE marking for the Multilisa® BICD2 test. BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).

Protagen launches first CE marked diagnostic assays Multilisa CENP-B and Scl-70 for the diagnosis of Systemic Sclerosis

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced the launch of its first CE marked diagnostic assays Multilisa® CENP-B and Multilisa® Scl-70 ELISA to aid in the diagnosis of Systemic Sclerosis (SSc).

Protagen AG have been nominated as one of three finalists in the 'Best Personalized Medicine Advance or Application' category of the prestigious Clinical and Research Excellence (CARE) awards

Protagen AG have been nominated based on the NavigAID Systemic Lupus Erythematosus (SLE) array that was developed using the proprietary Protagen SeroTag® technology.

NavigAID SLE measures autoantibodies associated specifically with SLE and also identifies subsets of autoantibodies associated with particular SLE disease states and pathologies. This is the first time it has been possible to differentiate between different SLE patient subgroups and currently this technology is being applied to the development of an SLE companion diagnostic with a global pharmaceutical partner.